AVIEW Lung Nodule CAD vs ElucidVivo A.3
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
AVIEW Lung Nodule CAD is primarily designed for comprehensive lung pathology detection and screening, including a feature for coronary artery calcification scoring. ElucidVivo A.3, conversely, is a specialized tool focused on detailed quantitative analysis of arterial plaque composition and stability for atherosclerosis patient stratification. While both leverage AI in cardiovascular imaging, their core applications and the depth of analysis in this domain are distinct.
Choose AVIEW Lung Nodule CAD if…
Choose AVIEW Lung Nodule CAD if your radiology department requires a comprehensive AI solution for lung cancer screening and follow-up. This tool excels at detecting, classifying, and quantifying pulmonary nodules, while also providing simultaneous analysis for emphysema and coronary artery calcification from chest CT scans, streamlining the assessment of multiple thoracic conditions.
View AVIEW Lung Nodule CAD →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if your cardiology or vascular surgery practice needs advanced, quantitative AI analysis of arterial plaque composition and stability from CT angiography. This system is ideal for stratifying atherosclerosis patients and optimizing treatment decisions by providing detailed visualization and measurement of plaque characteristics, validated against histology.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW Lung Nodule CAD | ElucidVivo A.3 |
|---|---|---|
| Deployment | On-premises and cloud environment | Cloud and on-premise secure deployment. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW Lung Nodule CAD | ElucidVivo A.3 |
|---|---|---|
| Name | AVIEW Lung Nodule CAD | ElucidVivo A.3 |
| Company | Coreline Soft Co. | Elucid Bioimaging |
| Primary AI Focus | Assists radiologists in detecting and analyzing pulmonary nodules on chest CT scans, and offers comprehensive screening for lung cancer, COPD, and coronary artery calcification. | Provides quantitative analysis of arterial plaque composition and stability from CT angiography, assisting physicians in atherosclerosis patient stratification and optimizing treatment decisions. |
| Key Analysis Capabilities (Specific) | AI-based pulmonary nodule detection (3-20 mm), Nodule classification (solid, part-solid, non-solid), 3D nodule size and volume quantification, Automatic report generation based on Lung-RADS classification, Nodule matching and volume doubling time (VDT) calculation for follow-up comparisons. | AI-powered quantitative analysis of arterial plaque, Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, Visualizes lesion-level plaque composition, Provides 3D visualization of highlighted vessels, Offers rotatable curved MPR vessel views and cross-sections. |
| Additional Quantitative Analysis | Quantitative emphysema analysis (e.g., Low Attenuation Area - LAA, emphysema index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass scores). | Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity. |
| Target Conditions | Lung cancer, COPD, Coronary Artery Calcification | Atherosclerosis |
Videos
Demos, reviews, and walkthroughs featuring AVIEW Lung Nodule CAD and ElucidVivo A.3.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
AVIEW Lung Nodule CAD (Tool A) is designed to assist radiologists in detecting and analyzing pulmonary nodules on chest CT scans, offering comprehensive screening for lung cancer, COPD, and coronary artery calcification. ElucidVivo A.3 (Tool B) provides quantitative analysis of arterial plaque composition and stability from CT angiography to assist physicians in atherosclerosis patient stratification and optimize treatment decisions.
AVIEW Lung Nodule CAD (Tool A) performs its analysis on chest CT scans. ElucidVivo A.3 (Tool B) requires CT angiography images to provide its quantitative analysis of arterial plaque.
Tool A's AI focuses on detecting and classifying lung nodules, quantifying emphysema, and scoring coronary artery calcification. Tool B's AI objectively quantifies specific arterial plaque components such as Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, and visualizes lesion-level plaque composition.
AVIEW Lung Nodule CAD (Tool A) provides 3D nodule size and volume quantification, automatic report generation based on Lung-RADS classification, volume doubling time, quantitative emphysema analysis, and Agatston, volume, and mass scores for coronary artery calcification. ElucidVivo A.3 (Tool B) quantifies LRNC, matrix, and calcifications from CT images and derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity.
AVIEW Lung Nodule CAD (Tool A) offers simultaneous analysis of lung nodules, emphysema, and coronary artery calcification (referred to as the 'Big 3') from chest CT scans. ElucidVivo A.3 (Tool B) focuses specifically on detailed arterial plaque composition and stability from CT angiography.
ElucidVivo A.3 (Tool B) explicitly states that its analysis of plaque characteristics is validated against ground-truth histology. AVIEW Lung Nodule CAD (Tool A) generates reports based on Lung-RADS classification and calculates volume doubling time for follow-up, implying clinical utility, but does not explicitly state validation against a specific ground-truth standard like histology in the provided description.